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Vitiligo is an acquired skin disease that significantly impacts the quality of life of patients. Medical treatment of vitiligo includes the
use of melanocyte transplant, but the results are variable. We have treated 4 patients with either focal or generalized stable vitiligo
using a graft of autologous melanocytes’ culture on a denuded amniotic membrane (AM). A culture biopsy was obtained in every
patient and grown in melanocytes’ media for 10–14 days after which cells were transferred to a denuded AM and transplanted into
the achromic lesions. Patients were followed for up to 6 months using clinical assessment of achromic lesions. Treated areas ranged
between 4 cm2 and 210.6 cm2. Response to treatment was excellent in all patients with 90–95% repigmentation success rate. Our
results demonstrate that transplantation of autologous melanocytes cultured on AM is a new, simple, and eﬀective treatment for
stable vitiligo.
1. Introduction
Vitiligo is an acquired skin disease that aﬀects 0.1–3% of
the world’s population, characterized by loss of melanocytes
from the epidermis, and leads to the development of
achromic lesions. The basic pathogenesis of vitiligo remains
unknown, although several studies suggest genetic pre-
disposition, relationship to other autoimmune disorders,
biochemical and neurohormonal imbalance, and environ-
mental toxin/stressors [1–3]. The cosmetic disfigurement
caused by vitiligo has profound psychological eﬀects in
approximately two-thirds of the patients, with depression,
low self-esteem, social rejection, and even job discrimination
[4]. In patients aﬀected by focal vitiligo, the causative factors
usually disappear, leaving well-defined achromic lesions. In
stable generalized vitiligo, the size and number of lesions are
stationary for several years and the Koebner phenomenon is
absent. Current conventional medical treatment of vitiligo
consists of UV therapy (narrowband UV-B or psoralen
plus UV-A), local steroids, tacrolimus, pimecrolimus, and
calcipotriol. In patients with stable vitiligo, lack of reliably
eﬀective medical therapies has led to the development of
surgical treatment options using transplantation of autol-
ogous melanocytes. This technique includes split-thickness
grafts, punch grafts, and suction blister grafts, which do not
require cell expansion [5, 6]. Complications of these surgical
methods can lead to the appearance of a cobblestone surface,
peripheral hypopigmentation, spotty pigmentation, or lack
of pigmentation of the treated areas, as well as to scarring
and pigmentary alterations of the donor sites [7]. Cur-
rently transplantation of cultured autologous melanocytes
with or without keratinocytes for treating vitiligo is at
the developmental stage. Such transplantation techniques
include noncultured epidermal suspension, cultured mixed
melanocyte-keratinocyte suspension with or without carrier,
and cultured pure melanocyte suspension [8, 9].
The amniotic membrane (AM), the inner part of the
placenta, consists of a thick basement membrane of collagen
type IV and laminin and an avascular stroma. Davis [10]
was the first to use fetal membranes in skin transplantation
in 1910. Subsequently, AM underwent widespread use as
biological dressing in the management of burns [11], chronic
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venous leg ulcers [12], toxic epidermal necrolysis [13],
epidermolysis bullosa [14], surgical dressings [15], and
following facial dermabrasion [16]. Since 1995, when Kim
and Tseng reported the use of preserved human AM to
rehabilitate severely damaged rabbit cornea [17], AM trans-
plantation has been successfully applied for ocular surface
reconstruction in patients with severe corneal diseases [18].
Experimental and clinical studies using AM as a
graft or patch have demonstrated that AM promotes re-
epithelialization, decreases inflammation and fibrosis, and
inhibits angiogenesis. AM acts like a basement membrane
and facilitates the migration of epithelial cells [19], has
an anti-inflammatory eﬀect by inhibiting protease activity
and infiltration of leukocytes and by suppressing IL-1α and
IL-1β [20], and induces downregulation of TGF-β thus
reducing fibrosis [21]. In addition, AM has antimicrobial
properties that decrease the risk of postoperative infection
[22]. Moreover, AM has been thought to display very low
immunogenicity. The technique of human AM processing
and cryopreservation with the Dulbecco Modified Eagle
Medium and 50% glycerol recommended by the FDA renders
all the amniotic cells nonviable [23].
In the current study, we report the clinical results
obtained with the application of melanocytes cultivated on
AM onto distinct achromic lesions.
2. Patients andMethods
2.1. Patients. The study was approved by the institu-
tional ethics committee, and written informed consent was
obtained from the patients or parents. From January 2005
to May 2006, 4 patients (1 male and 3 female) ranging in
age from 13 to 29 years, 2 with stable generalized vitiligo
and 2 with stable focal vitiligo were treated with autologous
transplantation of pure melanocytes using AM as a carrier
(Table 1). Stable disease was defined as no new lesions or
expansion of preexisting lesions in the last 12 months. All
patients had previously received several medical treatments
without response.
2.2. Amniotic Membrane. Placentas were obtained during
elective cesarean delivery from mothers who had been
screened for HIV, hepatitis B, hepatitis C, HTLV-1, CMV, and
syphilis at the time of birth, and 3 months after harvesting
the AMs. Under a laminar flow hood, the placenta was
washed free of all blood clots using balanced saline solution
containing 50 ug/mL streptomycin, 50 ug/mL penicillin, and
2.5 ug/mL amphotericin. The amnion was separated from
the rest of the chorion by blunt dissection. The membrane
was then flattened onto a nitrocellulose paper, with the
epithelium/basement membrane surface up. The membrane
and the paper were then cut up into 5 × 5 cm pieces and
placed in a sterile vial containing the Dulbecco Modified
Eagle Medium and glycerol in a ratio 1 : 1. The vials were
frozen at −80◦C. Immediately before use, AM was thawed
and washed with PBS. The pieces were then treated with
0.02% ethylenediamine tetraacetic acid (EDTA) in PBS at
37◦C for 2 h. The digested AM was gently scrubbed with a
plastic spatula to remove the epithelium without breaking
(a)
(b)
(c)
Figure 1: Piece of amniotic membrane (a); immunohistochemistry
for HMB-45 applied to cells cultured on slide. A large number of
melanocytes can be observed (b); micrograph of cross-sectioned
AM stained with HMB-45 after cell culture (c). Original magnifi-
cation: (b, c) X100.
the basement membrane. Acellularity of the scrubbed AM
was confirmed by H&E staining (Figure 1(a)). AM was
placed in a plastic frame before seeding of melanocytes.
2.3. Cell Culture. Melanocyte basal medium (MBM, Pro-
moCell, Heidelberg, Germany) without PMA (phorbol 12-
myristate 13-acetate) nor bovine pituitary extract, sup-
plemented with basic fibroblast growth factor (1 ng/mL),
human recombinant stem cell factor (50 ng/mL), and human
recombinant granulocyte/macrophage colony-stimulating
factor (10 ng/mL) for 10–14 days, was used for the
melanocyte culture.
A superficial shave biopsy (1 cm2) was taken from
pigmented buttock skin under local anesthesia. Skin samples
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Figure 2: Patient 1. Preoperatively (a); the achromic epidermis was removed using CO2 laser, and AM carrying cultured melanocytes on the
basement membrane surface was applied on the denuded area with one layer of Vaseline gauze. The amniotic membranes were fixed with
steri-strips and covered with dry gauze and adhesive tape (b); postoperative photography (>90% repigmentation at 16 weeks) (c).
Table 1
Patients Age, years/gender Type of vitiligo Grafted area Size, cm2 % repigmentation at 6 months
1 29/F Focal Areola and nipple 4 95
2 13/M Focal Chin 9 90
3 26/F Generalized Legs 185 90
4 17/F Generalized Legs 210 95
were washed in phosphate-buﬀered saline (PBS), and the
connective tissue was trimmed. The epidermis was separated
from the dermis with 1% Dispase II (Boehringer Mannheim,
Barcelona, Spain) in PBS with gentamicin (20mg/mL)
at 37◦C overnight. Epidermal sheets were peeled from
the dermis and stirred in 0.05% trypsin and 0.53mM
EDTA solution (trypsin-EDTA solution) for 10min at
37◦C. The trypsin-EDTA solution was inactivated with a
trypsin inhibitor (Sigma, Madrid, Spain) and centrifuged
at 1500 rpm for 5min. Cell pellets were resuspended in
10mL of supplemented MBM and cultured at 37◦C in a
humidified atmosphere containing 5% CO2 in 25 cm2 tissue
culture flasks (Nunclon, Roskilde, Denmark). When 80–90%
confluence was reached (Figure 1(b)), cells were digested
with 0.25% trypsin/0.02% EDTA and then replated into the
basement membrane side of AM prepared as described above
at a density of 5–25×103 cell/cm2.Melanocytes were cultured
for an additional 3-4 days and either transplanted onto the
denuded skin or fixed with formalin for immunohistochem-
ical staining.
2.4. Immunohistochemical Studies. To ensure the presence
of melanocytes, immunohistochemical staining for HMB-45
(1 : 100; Biogenex, San Ramon, Calif, USA) was performed
using the EnVision+ System (Dako, Glostrup, Denmark)
according to themanufacture’s recommendations. Both AMs
and cells cultured on chamber slides were fixed in 4% neutral
buﬀered formalin for 10min. After washing in PBS, free-
floating amniotic membranes and slides were permeabilized
with 5%Triton X-100 for 30min and endogenous peroxidase
activity was quenched with 3% H2O2 for 10min. Samples
were incubated with primary antibody overnight at 4◦C.
After rinsing, membranes and slides were incubated with
goat antimouse (K4001, Dako) labeled polymer for 30min
at room temperature. Cells were visualized by incubating the
sections with DAB+ (K3468, Dako). Washes between each
step were carried out with Tris-HCl 0.05M buﬀer, 0.5M
saline, pH 7.6 (TBS) containing 0.05% Tween 20 (TBS-
T). Slides were counterstained lightly with hematoxylin,
dehydrated in graded series of ethanol, cleared in xylene,
and mounted in DPX. Amniotic membranes were mounted
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Figure 3: Patient 3. Preoperatively (a), desepidermized lesion after treatment with CO2 laser (b), and postoperative photographs (>90%
repigmentation at 16 weeks) (c).
onto glass slides, dried overnight, cleared in xylene, and
coverslipped with DPX. Samples were examined on a Nikon
Eclipse E800M microscope, and 10 random images per slide
were captured with Analysis Soft Imaging System Gmbh
software. The number of melanocytes per mm2 was counted
using the ImageJ software.
2.5. Surgical Procedure. After disinfection with povidone-
iodine, under local anesthesia with lidocaine hydrochloride
(20mg/mL), epidermal ablation was performed using the
Silk Touch Flashscanner attached to a Sharplan 1030 CO2
laser at the setting of 5.5–7W with a 0.2-second pulse
duration (Laser Industries Ltd, Tel Aviv, Israel). To obtain an
adequate depth of the wound bed in the deepithelialization of
achromic areas, we ablated slightly less tissue than was nec-
essary to achieve pinpoint bleeding, which indicates penetra-
tion into the papillary dermis. One laser pass was suﬃcient
for all patients. After the papillary dermis was reached, the
denuded lesions were treated with the AMs containing cul-
turedmelanocytes. AMs with themelanocytes weremounted
on Vaseline gauze (LINITUL, Bama-Geve, Barcelona, Spain).
Each amniotic membrane (surface 12.56 cm2) was secured,
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with the basement membrane with cultured melanocytes
down, onto the denuded surface with one layer of Vaseline
gauze, steri-strips, and several layers of dry gauze and
traditional bandages.
Patients were asked to limit movement of the treated
region for 3-4 days. At that time the bandage was removed.
Two weeks after the procedure, all patients began to receive
sun exposure or UVA irradiation twice per week for approx-
imately 6 weeks to stimulate melanocyte proliferation.
3. Results
3.1. Cell Cultures’ Analysis. The presence of melanocytes in
the culture was confirmed on the basis of the morphology
of the cells and immunocytochemical analysis with HMB-
45. The number of melanocytes transplanted varied between
0.1 and 0.3 × 106 per membrane. When melanocytes were
transferred to AM, a parallel culture on chamber slides
was also performed, and the percentage of melanocytes was
greater than 90% in every case.
3.2. Clinical Outcome. Achromic epidermis was removed by
means of the CO2 laser. The largest area treated in one session
was 210 cm2, and the smallest treated lesion was 4 cm2.
Assessment of repigmentation was performed monthly for
up to 6 months in every patient. While responses were
observed after 2 months in some patients, the complete
evaluation of the percentage of repigmentation in all patients
was performed after 6 months (Figure 2).
Response to treatment was excellent in all patients
(Table 1). There were no diﬀerences in repigmentation
according to the concentration of melanocytes in the
graft. Interestingly, in all patients the marginal area of the
hypopigmented lesions was also repigmented, unlike what is
observed in other surgical procedures, where the edge of the
lesions remains depleted of melanocytes. On the other hand,
epidermis regeneration was completed 6 days after grafting,
and no scars were observed in the recipients’ areas (Figure 3).
4. Discussion
Despite the availability of various types of medical and
surgical treatments for vitiligo, the therapeutic response
of either focal or chronic stable generalized vitiligo to
conventional treatment is poor, with a significant number
of patients failing to respond with a satisfactory degree
of repigmentation [24]. Cellular grafting techniques have
advantages over tissue grafts such as punch grafts or suction
blister epidermal grafts, including greater uniformity of
pigmentation, lower risk of skin-texture abnormalities such
as cobblestoning, and the ability to cover larger areas of
vitiligo with smaller graft sizes. Noncultured epidermal sus-
pension transplantation in stable vitiligo was first described
by Gauthier and Surleve-Bazeille [25], and a recent paper
reports the use of this technique in children and adolescents
[26]. However, the donor skin size to recipient skin size
ratio is between 1 : 3 and 1 : 10. Expansion of melanocytes in
vitro provides more cells for transplantation; therefore, the
cells from a small piece of skin can be used to treat a large
vitiliginous area. One of the limitations of transplantation
of cultured melanocytes is the delivery of the cells in a
vehicle that facilitates the cells to engraft and remain in the
location of the skin lesion. Administration of cell suspensions
may lead to the disappearance of melanocytes while the
use of diﬀerent scaﬀolds may provide a better substrate for
engraftment. Recently we treated a group of five patients
with either focal or generalized stable vitiligo using a graft
of autologous melanocytes cultured on a denuded AM,
with very good repigmentation rates (90–100%) [27]. Here
we treated two patients with vitiligo lesions greater than
200 cm2 with similar satisfactory results. From the second
week the proliferation of melanocytes is exponential so that
large achromic areas have no direct therapeutic limitation.
The use of AM as a mean of providing a scaﬀold for
transplantation of melanocytes oﬀers several advantages: the
anti-inflammatory and antimicrobial properties of the AM
along with the lack of antigenicity facilitate the epithelization
of the skin and decrease scarring. The basement membrane
and its underlying extracellular matrix of AM containing
collagen type IV, type VII, and laminins-1 and -5 [28]
provide a natural substrate for cells and allow adhesion and
proliferation of melanocytes. For these reasons AM seems to
be a very good substrate for cultivating human melanocytes
similarly to what is observed with human limbal epithelial
cells [29]. Besides their biological properties, AMs are easy
to obtain and unexpensive, can be customized, and are
cosmetically desirable, avoiding the scars seen with the use
of split-thickness skin grafts.
It has been hypothesized that epidermal trauma (der-
mabrasion or laser) could be a melanocyte-stimulating
trigger to a reservoir of melanocytes, that is, hair follicles
and the surrounding skin. On the other hand, the induced
repigmentation might be postinflammatory, caused by the
release of inflammatory mediators after epidermal trauma.
We believe these are unlikely explanations for the observed
eﬀects in our patients in accordance to studies in which Van
Geel et al. [30] have shown that repigmentation induced by
epidermal ablation, UV therapy, and inflammatory media-
tors in placebo-treated lesions is extremely limited.
We also show that the use of CO2 laser allows precise
removal of the epidermis, preservation of the papillary
dermis, and absence of bleeding and inflammation being
a user-friendly procedure, fast and uniform unlike more
classical dermabrasion or diathermosurgery [31].
The results in this limited number of patients warrant
further studies to demonstrate the usefulness of the AM as
a scaﬀold for melanocytes. Only an intraindividual clinical
trial evaluating the usefulness of AM as a scaﬀold versus
the application of melanocytes in suspension can confirm
the greater eﬃciency of using a carrier for transporting and
transplanting the cells.
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